Evidence map›Paper›PMID 35339415›Full record

ArticleEuropean urology focus2022

Using Cell Lines To Guide Neoadjuvant Therapy in Bladder Cancer: COXEN and SWOG S1314.

Garrett M Dancik, Dan Theodorescu

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in European urology focus, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.1field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 1 country.

Garrett M DancikDepartment of Computer Science, Eastern Connecticut State University, Willimantic, CT, USA.
Dan TheodorescuDepartment of Surgery, Cedars-Sinai Medical Center, Los Angeles, CA, USA; Department of Pathology and Laboratory Medicine, Cedars-Sinai Medical Center, Los Angeles, CA, USA; Samuel Oschin Comprehensive Cancer Institute, Los Angeles, CA, USA. Electronic address: dan.theodorescu@cshs.org.
Eastern Connecticut State University · USSamueli Institute · US

Funding

Regulation and Targeting of CD24 in Bladder CancerR01CA075115 · NCI · UNIVERSITY OF VIRGINIA CHARLOTTESVILLE · PI THEODORESCU, DAN · 2003 to 2024
$7.0M
NCI NIH HHS R01 CA075115
6 · The paper itself

Abstract

There are no predictive biomarkers in clinical use for the neoadjuvant treatment of bladder cancer. Here we report on a recent randomized phase 2 trial validating the identification of predictive biomarkers using cell lines in the absence of patient response data.

Indexed as

Urinary Bladder NeoplasmsBiomarkersCell LineHumansNeoadjuvant TherapyBiomarkers

Identifiers

PMID35339415
PMCPMC10112179
OpenAlexW4220739441

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.